HC Wainwright Brokers Reduce Earnings Estimates for PLX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - HC Wainwright dropped their Q3 2025 earnings per share estimates for Protalix BioTherapeutics in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.04 per share for the quarter, down from their previous estimate of $0.07. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q4 2025 earnings at $0.05 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.35 EPS.

Separately, Wall Street Zen cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $15.00.

Protalix BioTherapeutics Price Performance

Shares of NYSE PLX traded up $0.08 during trading on Tuesday, reaching $1.66. 690,192 shares of the stock traded hands, compared to its average volume of 835,539. Protalix BioTherapeutics has a 52-week low of $0.89 and a 52-week high of $3.10. The company has a 50-day moving average of $1.49 and a 200-day moving average of $2.00. The stock has a market capitalization of $132.36 million, a P/E ratio of -12.77 and a beta of -0.21.

Institutional Trading of Protalix BioTherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new stake in Protalix BioTherapeutics during the 1st quarter worth about $39,000. Cascade Financial Partners LLC bought a new position in Protalix BioTherapeutics in the 2nd quarter worth about $25,000. Police & Firemen s Retirement System of New Jersey bought a new position in Protalix BioTherapeutics in the 2nd quarter worth about $27,000. Bank of America Corp DE increased its stake in Protalix BioTherapeutics by 364,766.7% in the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company's stock worth $32,000 after acquiring an additional 21,886 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Protalix BioTherapeutics in the 2nd quarter worth about $40,000. Hedge funds and other institutional investors own 16.53% of the company's stock.

Insider Transactions at Protalix BioTherapeutics

In related news, Director Aharon Schwartz acquired 129,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were acquired at an average price of $1.60 per share, with a total value of $206,400.00. Following the acquisition, the director owned 303,000 shares of the company's stock, valued at approximately $484,800. This trade represents a 74.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.50% of the company's stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.